Lord, Abbett & Co
AEGR

Lord, Abbett & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Lord, Abbett & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-876,217
Closed -$29.2M – 1036
2014
Q3 		$29.2M Sell
876,217
-1,224,565
-58% -$38M 0.07% 381
2014
Q2 		$67.5M Buy
2,100,782
+537,000
+34% +$20M 0.15% 183
2014
Q1 		$72.1M Buy
1,563,782
+122,322
+8% +$7.17M 0.16% 174
2013
Q4 		$102M Sell
1,441,460
-127,337
-8% -$9.74M 0.23% 117
2013
Q3 		$134M Sell
1,568,797
-815,502
-34% -$69.1M 0.31% 75
2013
Q2 		$151M Buy
+2,384,299
New +$127M 0.35% 64

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Lord, Abbett & Co's AEGR Position: Q4 2014 in Review

Lord, Abbett & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 876,217 shares — an estimated $29.2M sold.

Lord, Abbett & Co first reported a position in AEGR in Q2 2013 and held it in 6 quarters. The position peaked at $151M in Q2 2013. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Lord, Abbett & Co reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Lord, Abbett & Co sold 876,217 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $29.2M.
  • Lord, Abbett & Co first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 6 quarters.
  • Lord, Abbett & Co's Aegerion Pharmaceuticals position peaked at $151M in Q2 2013.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Lord, Abbett & Co's 13F filing for Q4 2014, filed 13 Feb 2015.